K. Badel

发表

Rapid mobilization of CD34+ cells following administration of the CXCR4 antagonist AMD3100 to patients with multiple myeloma and non-Hodgkin's lymphoma.

J. Dipersio, J. Liesveld, S. Devine, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Augmented mobilization and collection of CD34+ hematopoietic cells from normal human volunteers stimulated with granulocyte–colony‐stimulating factor by single‐dose administration of AMD3100, a CXCR4 antagonist

B. Wood, H. Broxmeyer, K. Badel, 2005, Transfusion.

AMD3100 plus G-CSF can successfully mobilize CD34+ cells from non-Hodgkin's lymphoma, Hodgkin's disease and multiple myeloma patients previously failing mobilization with chemotherapy and/or cytokine treatment: compassionate use data

G. Tricot, G. Bridger, K. Badel, 2008, Bone Marrow Transplantation.

A Pharmacokinetic‐pharmacodynamic Model for the Mobilization of CD34+ Hematopoietic Progenitor Cells by AMD3100

G. Bridger, K. Badel, W. Liles, 2005, Clinical pharmacology and therapeutics.

Improved mobilization of peripheral blood CD34+ cells and dendritic cells by AMD3100 plus granulocyte-colony-stimulating factor in non-Hodgkin's lymphoma patients.

Y. Gazitt, K. Badel, G. Calandra, 2007, Stem cells and development.

Treatment with plerixafor in non-Hodgkin's lymphoma and multiple myeloma patients to increase the number of peripheral blood stem cells when given a mobilizing regimen of G-CSF: implications for the heavily pretreated patient.

M. Territo, P. McCarthy, K. Badel, 2009, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

A phase II study of plerixafor (AMD3100) plus G-CSF for autologous hematopoietic progenitor cell mobilization in patients with Hodgkin lymphoma.

F. Gao, J. Dipersio, K. Badel, 2008, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Mobilization of peripheral blood stem cells for autologous transplant in non-Hodgkin's lymphoma and multiple myeloma patients by plerixafor and G-CSF and detection of tumor cell mobilization by PCR in multiple myeloma patients

H. Goldschmidt, A. Ho, G. Ehninger, 2010, Bone Marrow Transplantation.

The use of AMD3100 plus G-CSF for autologous hematopoietic progenitor cell mobilization is superior to G-CSF alone.

J. Dipersio, J. Liesveld, S. Devine, 2005, Blood.

Safety and preliminary efficacy of plerixafor (Mozobil) in combination with chemotherapy and G-CSF: an open-label, multicenter, exploratory trial in patients with multiple myeloma and non-Hodgkin's lymphoma undergoing stem cell mobilization

A. Nademanee, J. Liesveld, G. Bridger, 2010, Bone Marrow Transplantation.

Safety, Pharmacokinetics, and Antiviral Activity of AMD3100, a Selective CXCR4 Receptor Inhibitor, in HIV-1 Infection

Dominique Schols, M. Lederman, C. Flexner, 2004, Journal of acquired immune deficiency syndromes.

Cell Mobilization is Superior to G-CSF Alone The Use of AMD3100 Plus G-CSF for Autologous Hematopoietic Progenitor

J. Dipersio, J. Liesveld, S. Devine, 2013 .

AMD3100 Combined with Standard Doses of G-Csf Leads to Rapid, Consistent Mobilization of Hematopoietic Progenitor Cells in Patients with Non-Hodgkin’s Lymphoma (NHL) and Multiple Myeloma.

G. Tricot, M. Territo, P. McCarthy, 2004 .

Steady State Mobilization of Autologous Blood Stem Cells Using G-CSF and AMD3100 in Patients with Multiple Myeloma (MM).

G. Ehninger, K. Badel, G. Calandra, 2006 .

Treatment with AMD3100 in Multiple Myeloma or Non-Hodgkin’s Lymphoma Patients to Increase the Number of Peripheral Blood Stem Cells When Given with a Mobilizing Regimen of Chemotherapy and G-CSF.

A. Nademanee, J. Liesveld, L. Akard, 2004 .

Plerixafor (Mozobil) alone to mobilize hematopoietic stem cells from multiple myeloma patients for autologous transplantation.

N. Flomenberg, K. Badel, G. Calandra, 2010, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

AMD3100 with G-CSF for Autologous Peripheral Blood Progenitor Cell (PBPC) Mobilization in Non-Hodgkin’s Lymphoma (NHL) and Multiple Myeloma (MM): Mobilization, Engraftment, and Pharmacokinetics (PK).

K. Badel, G. Calandra, S. Douglas, 2006 .

Proof of activity with AMD11070, an orally bioavailable inhibitor of CXCR4-tropic HIV type 1.

Edwin DeJesus, M. Boffito, R. Wong, 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

A pharmacokinetic study of plerixafor in subjects with varying degrees of renal impairment.

M. Hard, K. Badel, G. Calandra, 2010, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.